Probiotics Interactions

In people whose immune systems are pharmacologically suppressed (for example by calcineurin inhibitors, mTOR inhibitors, corticosteroids, or mycophenolate), live probiotic organisms can occasionally cross the gut wall and enter the bloodstream, causing bacteremia, endocarditis, or sepsis. Case reports and a matched case-control study document Lactobacillus and Bifidobacterium bloodstream infections in transplant and oncology patients, with some strains naturally resistant to first-line antibiotics. The event is uncommon but serious.

Chemotherapy can lower infection-fighting white blood cells and damage the gut lining, allowing live organisms from probiotic supplements to cross into the bloodstream and cause serious infection.

Systemic antifungals (such as fluconazole, itraconazole, amphotericin B, and the echinocandins) can kill yeast-based probiotics such as Saccharomyces boulardii, blunting their benefit. Bacterial probiotics like Lactobacillus and Bifidobacterium are generally unaffected, because their cell structure differs from fungi.

Taken at the same moment, an antibiotic can kill bacterial probiotic organisms before they reach the gut, lowering the probiotic's benefit. Spacing the doses apart fixes it.

Prebiotics are non-digestible fibers (like inulin, FOS, and GOS) that some gut bacteria ferment for fuel. Pairing them with a probiotic creates what scientists call a 'synbiotic.' The pairing is plausible and generally well tolerated, but evidence that the combination clearly beats either ingredient on its own is mixed and depends on the condition and the specific strains used.

Vitamin D and probiotics act on overlapping pathways in the gut. Vitamin D supports vitamin D receptor (VDR) activity in the intestinal lining, which probiotics rely on for their anti-inflammatory and barrier-strengthening effects, while some probiotic strains appear to modestly raise circulating vitamin D. Randomized trials suggest combined supplementation can outperform either alone for some inflammatory and gut-barrier endpoints, though the evidence base is still limited.